The backbone of breast cancer patients’ NACT are taxanes, anthracyclines, and platinum‐based agents, along with anti‐HER2‐targeted therapy for those with HER2‐positive disease, and increasingly immunotherapy for those with triple‐negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and breast carcinoma.